Kwang Dong Pharmaceutical Co., Ltd. (009290.KS) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	1707.3B	1659.5B	1640.7B	1514.5B	1431.5B
Cost of Revenue	1406.6B	1366.3B	1341.4B	1219.3B	1149.5B
Gross Profit	300.7B	293.2B	299.3B	295.1B	282.0B
Operating Expenses
R&D Expense	7.9B	9.1B	10.1B	15.3B	9.7B
SG&A Expense	179.6B	154.1B	154.3B	233.8B	140.9B
General & Admin Expense	10.5B	13.7B	15.2B	15.2B	14.8B
Selling & Marketing Expense	140.3B	140.3B	139.1B	133.1B	126.1B
Other Expenses	82.3B	98.9B	104.8B	94.2B	93.2B
Total Operating Expenses	267.2B	262.2B	269.2B	249.1B	243.8B
Cost and Expenses	1673.7B	1628.5B	1610.6B	1465.7B	1393.3B
Operating Income (EBIT)	33.5B	31.0B	30.1B	48.8B	38.2B
Non-Operating
Interest Income	4.5B	3.8B	5.3B	4.5B	1.8B
Interest Expense	11.4B	11.0B	10.3B	6.9B	3.7B
Net Interest Income	(6.9B)	(7.2B)	(4.9B)	(2.4B)	(1.9B)
Other Non-Op Income/Expense	(631.2M)	(61.0M)	27.2B	251.7M	(2.0B)
Non-Operating Income (excl Interest)	(4.1B)	(10.9B)	(37.5B)	(13.3B)	(1.8B)
EBT (Pre-Tax Income)	32.9B	31.0B	57.3B	49.0B	36.3B
Income Tax Expense	10.0B	9.7B	15.5B	9.6B	9.6B
Bottom Line
Net Income	21.8B	21.0B	40.5B	37.0B	24.2B
Earnings from Cont. Ops	22.9B	21.3B	41.8B	39.4B	26.7B
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	21.8B	21.0B	40.5B	37.0B	24.2B
Per Share
Basic EPS	₩505	₩521	₩1,010	₩913	₩588
Diluted EPS	₩505	₩521	₩1,010	₩913	₩588
Revenue Per Share	₩29,342	₩31,657	₩40,990	₩37,421	₩34,847
Shares
Basic Shares Outstanding	58.2M	52.4M	40.0M	40.5M	41.1M
Diluted Shares Outstanding	58.2M	52.4M	40.0M	40.5M	41.1M
Profitability Metrics
EBITDA	(14.8B)	48.5B	44.6B	55.0B	54.0B
D&A	19.6B	17.5B	14.5B	12.9B	13.9B
EBIT	(34.4B)	31.0B	30.1B	42.1B	40.0B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026